

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

Authors

Javier Melchor, Marcos Garcia-Lacarte, Sara C. Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco J. Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose Angel Martinez-Climent, and Sergio Roa

Correspondence

sroa@unav.es

In Brief

Co-expression of MYC/BCL2 is an early pathogenic mechanism when typical mutations of activated B-cell-like (ABC) diffuse large B-cell lymphomas (DLBCL) are engineered preclinically (pBIC mice). In this scenario, the specific BCL2 inhibitor venetoclax cooperates with anti-CD20-based immunotherapy by licensing direct apoptosis of lymphoma cells and immunomodulating T-cell responses, which results in improved therapeutic responses.

